Newswise — New Brunswick, N.J., June 20, 2024 - Bolstered by $6.
3 million raised in donations, the Rutgers Board of Governors today approved the establishment of the William Hait Endowed Directorship at Rutgers Cancer Institute. Moving forward, the director of Rutgers Cancer Institute will be known as the William Hait Director. Recognized for his visionary leadership in the field of cancer research and patient care, William N.
“Bill” Hait, MD, PhD, is the executive vice president, chief external innovation and medical officer at Johnson & Johnson as well as the founding director of Rutgers Cancer Institute. During his 14-year tenure as director, he earned the Institute the prestigious National Cancer Institute (NCI) designation in 1997 – the first and only in New Jersey. He also led the center to achieve Comprehensive Cancer Center designation from the NCI in 2002, in a record amount of time.
Following his tenure at Rutgers Cancer Institute, Hait joined Johnson & Johnson in 2007 where he has served in various global leadership positions focusing his teams on the intersection of unmet medical needs and breakthrough science, transforming the lives of millions of patients around the world. He will retire from his current role at Johnson & Johnson in September. “On behalf of our faculty and staff, I thank the many donors who have made the William Hait Endowed Directorship possible,” said Steven K.
Libutti, MD, director of Rutgers Cancer Institute. “It is a fitting t.
